Celsion Presents BPH Study Results at 99th Annual American Urological Association Meeting.Business Editors/Health/Medical Writers COLUMBIA, Md.--(BUSINESS WIRE)--May 11, 2004 Celsion Corporation (AMEX AMEX See: American Stock Exchange :CLN) announced today that Dr. David Bock will be presenting two papers relating to its Prolieve(TM) Thermodilatation system for the treatment of Benign Prostatic Hyperplasia benign prostatic hyperplasia n. Abbr. BPH A nonmalignant enlargement of the prostate gland commonly occurring in men after the age of 50, and sometimes leading to compression of the urethra and obstruction of the flow of urine. (BPH) at the American Urological Association (AUA) annual meeting in San Francisco on Tuesday, May 11, 2004. The two papers are titled, "Prolieve Transurethral Microwave Thermodilatation Versus Finasteride Finasteride Definition Finasteride is a drug that belongs to the class of androgen inhibitors, which means that it blocks the production of male sex hormones. It is sold in the United States and Canada under the brand names Proscar and Propecia. - Results of a Multicenter, Randomized Trial in Symptomatic Patients with Benign Prostatic Hyperplasia" and "Safety and Effectiveness of Prolieve(TM) Transurethral Thermodilatation - Following Treatment with Finasteride for Symptomatic Benign Prostatic Hyperplasia." Celsion's Prolieve Thermodilatation system treats the symptoms of BPH, a condition affecting older men, more commonly referred to as an enlarged prostate. The Prolieve Thermodilatation system is a dual action technology employing heat and urethral dilatation (hence, "Thermodilatation") to provide significant symptomatic improvement in two weeks. The device is used in an office procedure that minimizes patient discomfort and the need for post-treatment catheterization catheterization Threading of a flexible tube (catheter) through a channel in the body to inject drugs or a contrast medium, measure and record flow and pressures, inspect structures, take samples, diagnose disorders, or clear blockages. . In a randomized one-year clinical trial, conducted at 14 centers across the United States, patients undergoing treatment with the Prolieve system achieved measurably greater improvement in symptoms after three months compared to a drug, Proscar(R) (distributed by Merck (NYSE NYSE See: New York Stock Exchange :MRK)) (Finasteride), which is commonly prescribed to treat this condition. The Prolieve system, which was approved by the FDA on February 19, 2004, is being distributed for Celsion Corporation by Boston Scientific Corporation (NYSE:BSX). Tony Deasey, Celsion's Executive Vice President and Chief Operating Officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. , said, "We are very pleased with the initial rollout of the Prolieve system. Equipment has been delivered to a dozen sites around the country and acceptance by both physicians and patients has been excellent." For information concerning treatment centers, please contact Dr. William Gannon, Celsion's Medical Director, at 800-262-0394. ABOUT CELSION: Celsion Corporation, based in Columbia, Maryland, is a biotechnology company dedicated to the development and commercialization of treatment systems for cancer and other diseases using focused-heat energy, either administered alone or in combination with other therapeutic devices, heat-activated genes and heat-activated drugs. In January 2003, Celsion entered into a strategic alliance with Boston Scientific Corporation (NYSE:BSX) in which Boston Scientific will initially distribute the Prolieve(TM) Thermodilatation system worldwide. Boston Scientific currently owns approximately 7% of Celsion's outstanding stock. Celsion has research, license or commercialization agreements with leading institutions such as the National Institute of Health, Duke University Medical Center, Massachusetts Institute of Technology Massachusetts Institute of Technology, at Cambridge; coeducational; chartered 1861, opened 1865 in Boston, moved 1916. It has long been recognized as an outstanding technological institute and its Sloan School of Management has notable programs in business, , Harbor UCLA Medical Center, Montefiore Medical Center and Memorial Sloan-Kettering Cancer Center The Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City is a cancer treatment and research institution founded in 1884 as the New York Cancer Hospital. The main campus is located at 1275 York Avenue, between 67th and 68th Streets, with other locations in New , Roswell Park Cancer Institute The Roswell Park Cancer Institute is a cancer research and treatment center located in Buffalo, New York. Founded in 1898 by Dr. Roswell Park, it was the first dedicated medical facility for cancer treatment and research in the United States. , and Duke University. For more information on Celsion, visit our website: www.celsion.com. Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion